On October 11-12, 2021, the two-day BPID 2021 Shanghai (Minhang) Biomedical Industry Innovation Summit was successfully held in Hongqiao, Shanghai. BRL Medicine was awarded the " Bio-Innovation Drug Most Growth Annual Award in 2021". The conference organizers invited Prof. Ming-Yao Liu, Chairman of BRL Medicine and Dr. Yang Gao, Chief Strategy Officer of BRL Medicine to participate in the summit forum and attend the award ceremony as representatives of outstanding domestic innovative drug companies.

The conference was hosted by Shanghai Association for Science and Technology and Shanghai Minhang Government, with the theme of "Biomedicine Empowers Minhang's High-Quality Development". In order to accelerate the construction of an innovative demonstration highland of biopharmaceutical industry that radiates the Yangtze River Delta and serves the whole China and the whole world.

Conference site

At the meeting, Professor Liu Mingyao, Chairman and Dr. Gao Yang, Chief Strategy Officer were invited to share the latest progress of gene therapy and cell therapy and host the Clinical Research and Registration Filing Summit Forum as the representatives of outstanding domestic innovative drug companies.

 Prof. Ming-Yao Liu, Chairman of BRL Medicine, gave a speech

Prof. Ming-Yao Liu, Chairman of BRL Medicine, said that there are still many limitations and challenges in the development of cell therapy and gene therapy drugs, such as high drug cost, long preparation cycle and limited efficacy in solid tumors. So, how can companies break through to achieve clinical translation of gene editing in response to the current barriers and pain points in the industry?

Prof. Ming-Yao Liu said, "In terms of cell therapy and gene therapy, BRL Medicine has always been a leader in both basic research and clinical translation in the international arena, and continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. In recent years, BRL Medicine has been committed to original technology research and development, and has successfully built five technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform and Enhanced T Cell Platforms. In the future, BRL Medicine will also continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. Driven by the era of new commercial civilization, BRL Medicine holds an open, shared, and win-win attitude, and works with global innovative biomedical ecological chain companies to accelerate the transformation and implementation of innovative drugs, so as to benefit global patients with genetic diseases and malignant tumors!

 Dr. Yang Gao, Chief Strategy Officer of BRL Medicine, presiding

Dr. Yang Gao, Chief Strategy Officer of BRL Medicine, who was invited to host the "Biologics Registration and Filing Meeting in China, U.S. and Europe", said, "The technology of gene and cell therapy products is rapidly iterating, the principle of action is complex, and the industry is developing rapidly. As an applicant, we need to keep an eye on regulatory developments, update our knowledge of regulations and technical guidelines, and communicate with regulators in a timely manner to ensure the successful development of gene and cell therapy products under the regulatory framework for the benefit of patients. All along, BRL Medicine has been adhering to a rigorous and conscientious attitude in CMC, strictly controlling product quality so as to ensure product efficacy."

BRL Medicine award as "Bio-Innovation Drug Most Growth Annual Award in 2021"

On the 11th of November, at the special dinner ceremony of "Pharma BIG Star", BRL Medicine was awarded the " Bio-Innovation Drug Most Growth Annual Award in 2021" for its outstanding industry influence, continuous innovation and high growth. Dr. Li Wei, Vice President of Biomedical and Clinical Sciences of BRL Medicine, accepted the award on behalf of BRL Medicine.

Award Ceremony Scene

In response to the award, Mr. Zaixi Xi, CEO of BRL Medicine, said, "This award not only recognizes BRL Medicine's rapid growth over the past few years, but also its ability in innovative R&D strength and translational operations. Since its establishment, BRL Medicine has been looking at the global market and comprehensively laying out the gene therapy and cell therapy fields. In the future, BRL Medicine will continue to adhere to technological innovation and strive to solve the core problems and technical problems in gene and cell therapy, and maintain comprehensive competitiveness in global translation, business model innovation, brand operation, strategic cooperation, public relations and other dimensions. We believe that in the near future, BRL Medicine will through innovation led by gene editing, develop breakthrough therapeutics，become the world's leading Cellular & Gene pharmaceutical company!”